Deep Dive Into ANI Prescribed drugs Inventory: Analyst Views (6 Rankings) – ANI Prescribed drugs (NASDAQ:ANIP)

Over the past three months, 6 analysts shared their evaluations of ANI Prescribed drugs ANIP, revealing various outlooks from bullish to bearish.

The desk under offers a snapshot of their current scores, showcasing how sentiments have advanced over the previous 30 days and evaluating them to the previous months.

The 12-month worth targets assessed by analysts reveal additional insights, that includes a mean goal of $87.5, a excessive estimate of $94.00, and a low estimate of $80.00. This present common has decreased by 2.23% from the earlier common worth goal of $89.50.

Decoding Analyst Rankings: A Detailed Look

The evaluation of current analyst actions sheds gentle on the notion of ANI Prescribed drugs by monetary consultants. The next abstract presents key analysts, their current evaluations, and changes to scores and worth targets.

| Analyst | Analyst Agency | Motion Taken | Ranking |Present Worth Goal| Prior Worth Goal |
|——————–|——————–|—————|—————|——————–|——————–|
|Vamil Divan |Guggenheim |Maintains |Purchase | $86.00|$86.00 |
|Oren Livnat |HC Wainwright & Co. |Maintains |Purchase | $94.00|$94.00 |
|Glen Santangelo |Jefferies |Proclaims |Purchase | $80.00|- |
|Ekaterina Knyazkova |JP Morgan |Proclaims |Obese | $85.00|- |
|Vamil Divan |Guggenheim |Raises |Purchase | $86.00|$84.00 |
|Oren Livnat |HC Wainwright & Co. |Maintains |Purchase | $94.00|$94.00 |

Key Insights:

• Motion Taken: Analysts adapt their suggestions to altering market circumstances and firm efficiency. Whether or not they ‘Preserve’, ‘Increase’ or ‘Decrease’ their stance, it displays their response to current developments associated to ANI Prescribed drugs. This info offers a snapshot of how analysts understand the present state of the corporate.
• Ranking: Analyzing traits, analysts supply qualitative evaluations, starting from ‘Outperform’ to ‘Underperform’. These scores convey expectations for the relative efficiency of ANI Prescribed drugs in comparison with the broader market.
• Worth Targets: Analysts predict actions in worth targets, providing estimates for ANI Prescribed drugs’s future worth. Inspecting the present and prior targets provides insights into analysts’ evolving expectations.

Navigating via these analyst evaluations alongside different monetary indicators can contribute to a holistic understanding of ANI Prescribed drugs’s market standing. Keep knowledgeable and make data-driven selections with our Rankings Desk.

Keep updated on ANI Prescribed drugs analyst scores.

If you’re all for following small-cap inventory information and efficiency you can begin by monitoring it right here.

Discovering ANI Prescribed drugs: A Nearer Look

ANI Prescribed drugs Inc develops, manufactures, and markets generic prescription prescribed drugs. It manufactures liquid, powder, and oral solid-dose merchandise. Its areas of product growth embody narcotics, oncolytics, hormones and steroids, and sophisticated formulations involving extended-release and mixture merchandise. A few of its generic merchandise embody Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The corporate operates in two segments which embody Uncommon Illnesses and Manufacturers, Generics, and Others. Its geographical segments are america and Canada, of which nearly all of its income comes from america.

ANI Prescribed drugs’s Financial Influence: An Evaluation

Market Capitalization: With restricted market capitalization, the corporate is positioned under trade averages. This displays a smaller scale relative to friends.

Income Progress: ANI Prescribed drugs’s outstanding efficiency in 3M is obvious. As of 31 December, 2024, the corporate achieved a formidable income progress charge of 44.75%. This signifies a considerable improve within the firm’s top-line earnings. As in comparison with its friends, the income progress lags behind its trade friends. The corporate achieved a progress charge decrease than the typical amongst friends in Well being Care sector.

Web Margin: ANI Prescribed drugs’s web margin is spectacular, surpassing trade averages. With a web margin of -5.61%, the corporate demonstrates sturdy profitability and efficient value administration.

Return on Fairness (ROE): The corporate’s ROE is a standout performer, exceeding trade averages. With a formidable ROE of -2.64%, the corporate showcases efficient utilization of fairness capital.

Return on Belongings (ROA): The corporate’s ROA is a standout performer, exceeding trade averages. With a formidable ROA of -0.83%, the corporate showcases efficient utilization of property.

Debt Administration: With a below-average debt-to-equity ratio of 1.55, ANI Prescribed drugs adopts a prudent monetary technique, indicating a balanced method to debt administration.

The Core of Analyst Rankings: What Each Investor Ought to Know

Benzinga tracks 150 analyst companies and studies on their inventory expectations. Analysts usually arrive at their conclusions by predicting how a lot cash an organization will make sooner or later, normally the upcoming 5 years, and the way dangerous or predictable that firm’s income streams are.

Analysts attend firm convention calls and conferences, analysis firm monetary statements, and talk with insiders to publish their scores on shares. Analysts usually charge every inventory as soon as per quarter or at any time when the corporate has a serious replace.

Analysts might complement their scores with predictions for metrics like progress estimates, earnings, and income, providing traders a extra complete outlook. Nonetheless, traders needs to be conscious that analysts, like every human, can have subjective views influencing their forecasts.

Which Shares Are Analysts Recommending Now?

Benzinga Edge provides you on the spot entry to all main analyst upgrades, downgrades, and worth targets. Kind by accuracy, upside potential, and extra. Click on right here to remain forward of the market.

This text was generated by Benzinga’s automated content material engine and reviewed by an editor.